Posts by: Jose Marques Lopes, PhD

News

Treatment with plant-derived salvianolic acid B (SAB) reduced skin fibrosis in a mouse model of scleroderma. The findings suggest that SAB may be an effective treatment for people with ... Read more

January 10, 2019January 10, 2019

Phase 2a Trial Will Evaluate GLPG1690 in Diffuse Cutaneous Scleroderma

News

A Phase 2a clinical trial will test the investigational therapy GLPG1690 in patients with diffuse cutaneous scleroderma. The double-blind, placebo-controlled Phase 2a study, called NOVESA (NCT03798366), will evaluate the ... Read more

December 6, 2018December 6, 2018

TAK242 Prevents and Reverses Fibrosis in Mice, Could Be Potential Scleroderma Therapy, Study Suggests

News

Inhibiting a key innate immunity protein known as TLR4 with a compound called TAK242 prevented and reversed skin and lung fibrosis (scarring) in mouse models, and eased the production ... Read more

November 15, 2018November 15, 2018

FAM111B Gene Mutations Not Associated with Scleroderma, Study Finds

News

Mutations in the FAM111B gene are rare in scleroderma patients and not associated with disease development, according to new research. This finding was reported in the study, “Mutations of FAM111B gene ... Read more

August 28, 2018August 28, 2018

Combined Measurement of 2 New Serum Biomarkers May Speed Diagnosis of SSc-PAH Patients

News

Patients with scleroderma and pulmonary arterial hypertension (PAH) have increased levels of two serum proteins, midkine (MDK) and follistatin-like 3 (FSTL3), according to a new study. The finding indicates ... Read more

August 9, 2018August 9, 2018

Lupus Overlap in Scleroderma Patients Does Not Seem to Affect Survival, Study Shows

News

Patients with both scleroderma and systemic lupus erythematosus (SLE) are younger at diagnosis, are more often women, and have less skin manifestations, but most importantly, show similar survival rates ... Read more

August 7, 2018August 7, 2018

HMGB1 Protein May Drive Blood Vessel, Tissue Damage in Scleroderma, Study Suggests

News

A protein involved in inflammation and tissue regrowth — HMGB1 — may be the main driver of blood vessel damage and tissue fibrosis in scleroderma, suggesting its potential as ... Read more

July 24, 2018July 24, 2018

Innate Immunity Protein a Potential Therapeutic Target in Scleroderma, Study Suggests

News

A key innate immunity protein called TLR4 is a key driver of organ fibrosis, according to a new study conducted in mice and scleroderma patients. The finding suggests that ... Read more

June 7, 2018June 7, 2018

Opsumit and Esbriet Combo Improves Scleroderma-related Interstitial Pneumonia and PAH, Case Report Shows

News

Treatment with Opsumit (macitentan) and Esbriet (pirfenidone) provided stable improvements in a scleroderma patient with interstitial pneumonia and borderline pulmonary arterial hypertension (PAH), according to a Japanese case report. The ... Read more

April 19, 2018April 19, 2018

Venous Blood Clots Do Not Increase Mortality in Scleroderma Patients, Study Shows

News

The occurrence of blood clots in the veins of scleroderma patients is rare and does not change patients’ survival rates, a new Canadian study shows. Still, researchers see a need ... Read more

Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

Plant-derived Compound May Treat Skin Fibrosis in Scleroderma, Study Suggests

Phase 2a Trial Will Evaluate GLPG1690 in Diffuse Cutaneous Scleroderma

TAK242 Prevents and Reverses Fibrosis in Mice, Could Be Potential Scleroderma Therapy, Study Suggests

FAM111B Gene Mutations Not Associated with Scleroderma, Study Finds

Combined Measurement of 2 New Serum Biomarkers May Speed Diagnosis of SSc-PAH Patients

Lupus Overlap in Scleroderma Patients Does Not Seem to Affect Survival, Study Shows

HMGB1 Protein May Drive Blood Vessel, Tissue Damage in Scleroderma, Study Suggests

Innate Immunity Protein a Potential Therapeutic Target in Scleroderma, Study Suggests

Opsumit and Esbriet Combo Improves Scleroderma-related Interstitial Pneumonia and PAH, Case Report Shows

Venous Blood Clots Do Not Increase Mortality in Scleroderma Patients, Study Shows

Pin It on Pinterest